DRD3 and glioblastoma: However, 10 μM of six of the DRD3 antagonists (SRI-21979, SRI-30052, SRI-26080, SRI-28414, SRI-30347, and SRI-27612) was sufficient to prevent GBM growth (Figs 1 and 2).